SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Belanger who wrote (539)8/20/1997 12:19:00 PM
From: David Bogdanoff   of 2173
 
Richard;

I would not think that the increased insulin usage is primarily in the placebo group because they did not mention that favorable development.
Yes, diabetes is a complicated disease and no new treatments have been marketed for decades; that's why there is market opportunity for Amylin. But they have to take advantage of it, not come up with weak excuses for weak results. Phase 3 trials are conducted after phase 1 and phase 2 trials; they had plenty of opportunity to observe insulin usage and design a correct phase 3 study program.

Frankly, investors should be satisfied to accept the conclusion that the study was poorly designed; it is easier to correct than a weak drug. :)

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News